The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load

Bone

Volumn 40, Issue 1, 2007, Pages 182-188

  Generali, Daniele ^a   Berruti, Alfredo ^b   Tampellini, Marco ^b   Dovio, Andrea ^c   Tedoldi, Sara ^a   Bonardi, Simone ^a   Tucci, Marcello ^b   Allevi, Giovanni ^a   Aguggini, Sergio ^a   Milani, Manuela ^a   Bottini, Alberto ^a   Dogliotti, Luigi ^b   Angeli, Alberto ^c  

^a Breast Unit   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Bone metastasis; Bone turnover markers; Breast cancer; Circadian rhythm

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CANCER PATIENT; CANCER RELAPSE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; MENOPAUSE; OSTEOLYSIS; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; SKELETON; STATISTICAL MODEL; URINALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CIRCADIAN RHYTHM; FEMALE; HUMANS; MIDDLE AGED; TUMOR BURDEN;

EID: 33751522658     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.06.023     Document Type: Article

References (26)

1. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev., Cancer 2 (2002) 584-593
2. Lipton A. Management of bone metastases in breast cancer. Curr. Treat Options Oncol. 6 (2005) 161-171
3. Gralow J.R. Optimizing the treatment of metastatic breast cancer. Breast. Cancer Res. Treat. 89 Suppl 1 (2005) S9-S15
4. Lowrey P., and Takahashi J.S. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu. Rev. Genomics Hum. Genet. 5 (2004) 407-441
5. Lévi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2 (2001) 307-315
6. Sephton S.E., Sapolsky R.M., Kraemer H.C., and Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 92 (2000) 994-1000
7. Bjarnason N.H., Henriksen E.E.G., Alexandersen P., Christgau S., Henriksen D.B., and Christiansen C. Mechanism of circadian variation in bone resorption. Bone 30 (2002) 307-313
8. Fu L., Patel M.S., Bradley A., Wagner E.F., and Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell 122 (2005) 803-815
9. Khosla S., and Kleerekoper M. Biochemical markers of bone turnover. In: Favus M.J. (Ed). Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. (2003), The American Society for Bone and Mineral Research, Washington DC 166-172
10. Srivastava A.K., Vliet E.L., Lewiecki E.M., Maricic M., Abdelmalek A., Gluck O., et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr. Med. Res. Opin. 21 (2005) 1015-1026
11. Berruti A., Dogliotti L., Gorzegno G., Torta M., Tampellini M., Tucci M., et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin. Chem. 45 (1999) 1240-1247
12. Eastell R., Calvo M.S., Burritt M.F., Offord K.P., Russell R.G., and Riggs B.L. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J. Clin. Endocrinol. Metab. 74 (1992) 487-494
13. Fraser W.D., Anderson M., Chesters C., Durham B., Ahmad A.M., Chattington P., et al. Circadian rhythm studies of serum bone resorption markers: implications for optimal sample timing and clinical utility. In: Eastell R., Baumann M., Hoyle N.R., and Wieczorek L. (Eds). Bone markers. Biochemical and clinical perspectives (2001), Martin Dunitz Ltd, London 107-118
14. Srivastava A.K., Bhattacharyya S., Li X., Mohan S., and Baylink D.J. Circadian and longitudinal variation of serum C-telopeptide, osteocalcin, and skeletal alkaline phosphatase in C3H/HeJ mice. Bone 29 (2001) 361-367
15. Rejnmark L., Vestergaard P., Heickendorff L., Andreasen F., and Mosekilde L. Loop diuretics alter the diurnal rhythm of endogenous parathyroid hormone secretion. A randomized-controlled study on the effects of loop- and thiazide-diuretics on the diurnal rhythms of calcitropic hormones and biochemical bone markers in postmenopausal women. Eur. J. Clin. Invest. 31 (2001) 764-772
16. Qvist P., Christgau S., Pedersen B.J., Schlemmer A., and Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31 (2002) 57-61
17. Caillot-Augusseau A., Vico L., Heer M., Voroviev D., Souberbielle J.C., Zitterman A., et al. Space flight is associated with rapid decreases of undercarboxylated osteocalcin and increases of markers of bone resorption without changes in their circadian variation: observations in two cosmonauts. Clin. Chem. 46 (2000) 1136-1143
18. Ju H.S., Leung S., Brown B., Stringer M.A., Leigh S., Scherrer C., et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin. Chem. 43 (1997) 1570-1576
19. Walton R.J., Preston C.J., Russell R.G., and Kanis J.A. An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease. Clin. Chim. Acta 63 (1975) 227-229
20. Fohr B., Dunstan C.R., and Seibel M.J. Clinical review 165: markers of bone remodeling in metastatic bone disease. J. Clin. Endocrinol. Metab. 88 (2003) 5059-5075
21. Duda Jr. R.J., O'Brien J.F., Katzmann J.A., Peterson J.M., Mann K.G., and Riggs B.L. Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J. Clin. Endocrinol. Metab. 66 (1988) 951-957
22. Pavlakis N., Schmidt R., and Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 3 (2005) [CD003474; doi:10.1002/14651858.CD003474.pub2]
23. Coleman R.E. The role of bisphosphonates in breast cancer. Breast 13 Suppl 1 (2004) S19-S28
24. Leyvraz S., Hess U., Flesch G., Bauer J., Hauffe S., Ford J.M., et al. Pharmacokinetics of pamidronate in patients with bone metastases. J. Natl. Cancer Inst. 84 (1992) 788-792
25. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
26. Bottini A., Generali D., Berruti A., Tampellini M., Torta M., Tedoldi S., et al. Increased antiresorptive activity of zoledronic acid administered in the night as compared to morning administration in breast cancer patients with bone metastases. ASCO Annual Meeting, June 2-6, 2006 Atlanta, U.S. Georgia (2006) abs